Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098358 | 1.00 | DNM1 (0.39) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL7541774 | 0.90 | ANPEP (0.40) | DNM1ALDH1A1TSHRGNAI3GNAO1 | |
| SCHEMBL1330042 | 0.76 | DNM1 (0.62) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL27835122 | 0.76 | DNM1 (0.62) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1289118 | 0.76 | DNM1 (0.62) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL9705885 | 0.74 | GNAI3 (0.50) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL17422642 | 0.74 | DNM1 (0.59) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Water SCHEMBL2517229 | 0.74 | DNM1 (0.59) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL17422661 | 0.74 | DNM1 (0.59) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10567288 | 0.73 | GPR84 (0.46) | GPR84FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | WOODLE MARTIN C (US) | 2003-09-04 | — | — | US | disclosed |
| EP-1242609-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | Novartis AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049324-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | NOVARTIS AG (CH) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | FUS, HNRNPUL2, HNRNPH1 | DNM1 3279/4885MEN1 2740/4885KMT2A 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.